Is RNN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

618 people get RNN articles and Market Currents by email alert.

Get email alerts on RNN »

HEADLINES:

Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013

Business Wire (Apr 2, 2013)
Rexahn Pharmaceuticals to Present at the 25th Annual ROTH Conference

Business Wire (Mar 11, 2013)
Rexahn Pharmaceuticals Provides Key Goals for 2013

Business Wire (Feb 19, 2013)
Cancer Stocks To Watch
BuySellShort • Mon, Feb 11 • 4 Comments
Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer

Business Wire (Jan 22, 2013)
Rexahn Pharmaceuticals Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds

Business Wire (Dec 17, 2012)
Rexahn Pharmaceuticals Closes Public Offering for $6,600,000 in Gross Proceeds

Business Wire (Dec 4, 2012)
Rexahn Pharmaceuticals Prices Public Offering of Stock

Business Wire (Nov 29, 2012)
Rexahn Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrant

Business Wire (Nov 28, 2012)
Teva Pharmaceutical to Increase Ownership in Rexahn

Business Wire (Nov 28, 2012)
Rexahn Pharmaceuticals Issued US Patent for Quinoxalinyl-piperazine Compounds

Business Wire (Nov 21, 2012)
Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds

Business Wire (Sep 26, 2012)
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference

Business Wire (Sep 6, 2012)
Rexahn Pharmaceuticals Provides Update on 2012 Strategic Goals

Business Wire (Sep 4, 2012)
Rexahn Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference

Business Wire (Aug 30, 2012)
Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer

Business Wire (Aug 28, 2012)
Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117

Business Wire (Aug 6, 2012)
Rexahn Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902

Business Wire (Jul 2, 2012)
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117

Business Wire (May 30, 2012)
Rexahn Pharmaceuticals: Update On Cancer Drugs
Roy Manning III • Thu, May 17, 2012 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Rexahn Pharmaceuticals: Update On Cancer Drugs
Roy Manning III • Thu, May 17, 2012 • 4 Comments
Rexahn Pharmaceuticals Focus On Cancer May Pay Off
Roy Manning III • Fri, Mar 30, 2012
Rexahn Is a Bargain Buy
Jeremy Richards • Tue, May 31, 2011 • 6 Comments
Rexahn Pharma Reports Two-Thirds of Patients Enrolled in Key Clinical Trial
M. E. Garza • Fri, May 6, 2011 • 5 Comments
Technical Analysis: Rexahn Pharmaceuticals
M. E. Garza • Tue, Feb 8, 2011 • 15 Comments
Rexahn Pharma Presents a Landmark in Clinical Trial Data Interpretation
Derek Lowe • Sun, Apr 18, 2010 • 11 Comments

Cancer Stocks To Watch
BuySellShort • Mon, Feb 11 • 4 Comments
Jazz Pharmaceuticals Can Hit An Interesting Note In 2012
Jessica King Holden • Sun, Feb 26, 2012 • 2 Comments
Inhibitex: This Is One You Might Want To Grow With
John Mylant • Wed, Nov 9, 2011
7 Big New Insider Stock Buys
Rougemont • Thu, Sep 15, 2011 • 1 Comment
7 Cheap Biotechs That Could Double Or Triple By Next Year
Rougemont • Mon, Sep 12, 2011 • 7 Comments
Hunting for the Next Dendreon
Michael J. Ray • Mon, Jul 11, 2011 • 9 Comments
5 Dirt Cheap Biotech Stocks Poised to Triple
Rougemont • Tue, Jun 28, 2011 • 3 Comments
6 Prime Biotechs for Short- and Long-Term Gains
James Stocklasar Thomas Jr. • Tue, May 31, 2011 • 10 Comments
16 Small Caps With Cash to Cover 1+ Years of Operating Expenses
Kapitall • Wed, Apr 20, 2011 • 2 Comments
5 Healthcare Stocks That Insiders Are Buying Now
Rougemont • Tue, Apr 12, 2011 • 2 Comments
7 Stocks With CEO Buys of at Least $96,000 in the Past Week
The Keating Letter • Thu, Apr 7, 2011
Rexahn Surprises Investors With Timing of Financing Announcement
M. E. Garza • Tue, Mar 29, 2011 • 7 Comments
Rexahn: Recent Concerns Overshadowing a Robust Pipeline?
James Stocklasar Thomas Jr. • Thu, Mar 17, 2011 • 26 Comments
Rexahn Pharma Is Considerably Undervalued Based on Prospects, Recent Developments
Jeremy Richards • Sun, Jan 23, 2011 • 8 Comments
Rexahn Should Run Again
M. E. Garza • Tue, Apr 20, 2010 • 9 Comments
Trading Updates for Rexahn, Neostem and Radient
M. E. Garza • Thu, Apr 15, 2010 • 15 Comments
Rexahn: The Undiscovered Biotech
M. E. Garza • Wed, Feb 10, 2010 • 5 Comments

There are no Transcripts on RNN.

Rexahn Pharmaceuticals to Present data on the Mechanism of action of RX-5902: A first-in-class inhibitor of p68 helicase for the treatment of solid tumors at AACR Annual Meeting 2013

Business Wire (Apr 2, 2013)
Rexahn Pharmaceuticals to Present at the 25th Annual ROTH Conference

Business Wire (Mar 11, 2013)
Rexahn Pharmaceuticals Provides Key Goals for 2013

Business Wire (Feb 19, 2013)
Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer

Business Wire (Jan 22, 2013)
Rexahn Pharmaceuticals Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds

Business Wire (Dec 17, 2012)
Rexahn Pharmaceuticals Closes Public Offering for $6,600,000 in Gross Proceeds

Business Wire (Dec 4, 2012)
Rexahn Pharmaceuticals Prices Public Offering of Stock

Business Wire (Nov 29, 2012)
Rexahn Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrant

Business Wire (Nov 28, 2012)
Teva Pharmaceutical to Increase Ownership in Rexahn

Business Wire (Nov 28, 2012)
Rexahn Pharmaceuticals Issued US Patent for Quinoxalinyl-piperazine Compounds

Business Wire (Nov 21, 2012)
Rexahn Pharmaceuticals Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds

Business Wire (Sep 26, 2012)
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference

Business Wire (Sep 6, 2012)
Rexahn Pharmaceuticals Provides Update on 2012 Strategic Goals

Business Wire (Sep 4, 2012)
Rexahn Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference

Business Wire (Aug 30, 2012)
Rexahn Pharmaceuticals, Seven Arts Pictures Gapping Up Wednesday

at Fox Business (Aug 29, 2012)
Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients with Metastatic Pancreatic Cancer

Business Wire (Aug 28, 2012)
Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study of RX-3117

Business Wire (Aug 6, 2012)
Rexahn Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902

Business Wire (Jul 2, 2012)
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117

Business Wire (May 30, 2012)
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA

Business Wire (May 8, 2012)

RNN vs. ETF Alternatives

Company Description

Currently, there's no company description for RNN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, January 30, 11:13 AM Rexahn Pharmaceuticals (RNN +3.3%) moves up this morning after being initiated by analysts at Maxim with a Buy and a price target of $1.50 a share. The company specializes in oncology and CNS therapeutics, and has recently expanded its intellectual property around isoquinolinamine, a class of potent anti-cancer compounds, which provide potent anti-tumor activities in several human cancer cell lines, such as breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma. Comment! [Healthcare, On the Move]
Tuesday, January 22, 11:48 AM Rexahn Pharmaceuticals (RNN +4.9%) trades higher today after saying it's appointed Dr. Peter D. Suzdak as its new chief executive officer. Dr. Suzdak succeeds Dr. Chang Ahn, who was recently appointed as the company's chief scientist. Dr. Ahn will also remain as chairman of the company's board of directors. Comment! [Healthcare, On the Move]
Wednesday, November 28, 2012, 4:47 PM Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering. Comment! [Healthcare]
Wednesday, November 28, 2012, 12:53 PM Rexahn Pharmaceuticals (RNN +9%) trades higher after the company said that Teva Pharmaceutical (TEVA -0.6%) will provide an additional $750K in funding to the company. Pursuant to the terms of an earlier agreementl, TEVA will purchase RNN's common stock at 120% of its closing price on the last trading day preceding the closing. TEVA has also agreed to commit additional research funding for development of RX-3117, a potential treatment for solid tumors including colon, lung and pancreatic cancers, and will retain the right to file the Investigational New Drug application with the FDA. 2 Comments [Healthcare, On the Move]
Friday, July 6, 2012, 1:15 PM Off-radar microcap Rexahn Pharmaceuticals (RNN) is up another +16.6% today, having doubled since Monday's announcement that it's submitted an IND application to the FDA for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. 4 Comments [Healthcare, On the Move]
Tuesday, February 8, 2011, 9:00 AM Premarket gainers: RHB +46%. KND +26%. CNXT +17%. XIDE +15%. SOMX +6%. CXZ +5%. CPST +5%. MT +5%. BYD +4%. MGM +4%. NTWK +4%. MOTR +4%. CCME +4%.
Losers: BR -12%. GLUU -7%. OLP -6%. TEVA -5%. RNN -5%. BBEP -5%. PPNT -5%. AVP -4%. KTOS -4%. Comment!
Thursday, December 2, 2010, 9:00 AM Premarket gainers: WBD +30%. RNN +22%. PSS +16%. ANF +8%. WTSLA +8%. S +8%. FNSR +6%. SGMO +5%. STP +4%.
Losers: SQNM -9%. ARO -9%. SEP -4%. AEO -4%. Comment!
Tuesday, October 19, 2010, 9:15 AM Premarket gainers: CTIC +14%. MEE +10%. PH +9%. RNN +7%.
Losers: INFN -33%. CWTR -29%. OGXI -15%. KCI -13%. BXC -11%. HT -7%. BKCC -7%. NVO -7%. VMW -7%. AIB -6%. ABK -5%. RIO -5%. ALU -5%. AAPL -5%. HL -4%. IBM -4%. RCL -4%. AUY -4%. ARMH -4%. WFT -4%. BHP -4%. SLW -4%. TOT -4%. Comment!
Thursday, September 2, 2010, 9:00 AM Premarket gainers: OREX +27%. BKC +21%. CRME +12%. RNN +12%. CERS +8%. CTIC +5%. WEN +4%. MPEL +4%.
Losers: PSS -6%. Comment!
Wednesday, June 23, 2010, 9:05 AM Premarket gainers: JBL +11%. KMX +10%. RAD +10%. RNN +7%. SAY +5%. CTIC +4%. LYG +4%. ACAS +4%. VG +4%.
Losers: RGLD -5%. Comment!
Thursday, May 13, 2010, 9:00 AM Premarket gainers: SY +15%. PUDA +15%. TGB +10%. NNA +9%. WFMI +6%. DVAX +6%. RNN +5%. IMMU +4%. EBAY +4%. CLNE +4%.
Losers: RAS -9%. RPT -8%. AGEN -5%. VNR -5%. IRE -4%. WES -4%. Comment!
Wednesday, April 28, 2010, 9:10 AM Premarket gainers: NBG +10%. TSFG +8%. CIIC +7%. NVAX +8%. BCRX +7%. RFMD +6%. TLAB +6%. ACAS +6%. RNN +6%. YRCW +5%. ABK +5%. PCBC +5%. MPEL +5%. ERIC +5%. UAUA +4%. LCC +4%. DCTH +4%. TMO +4%. CRBC +4%. CMCSA +4%. GT +4%. CHU +4%. SQNM +4%.
Losers: BWLD -19%. RHI -11%. CNXT -10%. FBC -10%. PFCB -4%. 1 Comment
Monday, April 19, 2010, 9:00 AM Premarket gainers: CRN +35%. YMI +9%. CTIC +5%. IMMU +4%. SQNM +4%.
Losers: RNN -13%. TSFG -7%. SPF -7%. PALM -6%. FRE -5%. FNM -5%. Comment!
Thursday, April 15, 2010, 9:00 AM Premarket gainers: ME +38%. ANDS +25%. AEZS +20%. IDIX +16%. TSFG +15%. IOC +9%. PPHM +10%. ABK +8%. CPBY +8%. IMGN +8%. RNN +7%. SIRI +6%. XOM +6%. JOEZ +6%. END +5%. YRCW +5%. AVNR +5%. UPS +4%. MDVN +4%. SOLR +4%. SGY +4%.
Losers: SNTS -34%. TITN -13%. NEP -9%. SMOD -6%. REVU -6%. MAC -6%. MGM -6%. AGEN -4%. APA -4%. BPOP -4%. Comment!
Wednesday, April 14, 2010, 9:00 AM Premarket gainers: KLIC +21%. ABK +19%. CRXX +17%. RNN +9%. HOTT +8%. SIRI +7%. PAL +6%. AIB +6%. TLAB +5%. FNM +6%. INTC +4%. AMD +4%. ERIC +4%. MBI +4%. VVUS +4%. PALM +4%.
Losers: NBG -4%. Comment!
Monday, April 12, 2010, 9:20 AM Premarket gainers: DCP +48%. WEL +26%. DBTK +15%. ABK +15%. RNN +14%. MIR +163%. RRI +13%. PALM +8%. FCEL +7%. KERX +6%. AVNR +6%. ICOC +6%. CPKI +5%. JUEZ +5%. CIEN +5%. DYN +4%. UBS +4%.
Losers: CLNE -7%. Comment!

Shane Skinner
Check out my article on Rexahn ($RNN) on my instablog!
Jan 3, 1:47 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Roy Manning III
Working on an article on RNN. New focus on cancer drugs looks good to me. Possible partnership on Archexin when results come in Q3.
3/29/12
Reply (1)

• !Report Abuse
View all 1 replies
PAULNMYSTI: Thinking the same. This drug has blockbuster potential, since it will be the first of its kind in treating pancreatic cancer.
7/19/12
• !Report Abuse
Add a reply...

140 characters

cshah2990
I want RNN go crazy
9/22/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

James Stocklasar Thomas Jr.
RNN pps 'bobs and weaves' but could go to the dance in a heart-beat
6/7/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

James Stocklasar Thomas Jr.
Move to biotech sector and safeguard your investment: ZLCS, AEZS, ASTX, BPAX, ATRS, RNN, GALE, SRPT
6/3/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

fasterthanc3
RNN has Frederick Frank as part of their team.His indep consultation RNN has the Serdaxin Phase IIb results at this years negotiating table
5/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Trio3: Frank was the best in the biotech business in the 80's, 90's and early 2000's. He's still at it and can only be positive for RNN.
7/7/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Will be closing out the $RNN trade likely where I opened it. It was meant as a daytrade but chart looks great. Sticking to discipline
5/12/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Initiated Short-term Trade in $RNN w/ tight stop losses. Market not so hot today so RNN could fall at any time if markets dont hold
5/12/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

James Stocklasar Thomas Jr.
RNN ran UP UP UP today
5/10/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

James Stocklasar Thomas Jr.
RNN lags at 1.15 after recent fund-raising. Could be a while before it begins to go back up
4/25/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Roy Manning III
Working on an article on RNN. New focus on cancer drugs looks good to me. Possible partnership on Archexin when results come in Q3.
3/29/12
Reply (1)

• !Report Abuse
View all 1 replies
PAULNMYSTI: Thinking the same. This drug has blockbuster potential, since it will be the first of its kind in treating pancreatic cancer.
7/19/12
• !Report Abuse
Add a reply...

140 characters

fasterthanc3
RNN has Frederick Frank as part of their team.His indep consultation RNN has the Serdaxin Phase IIb results at this years negotiating table
5/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Trio3: Frank was the best in the biotech business in the 80's, 90's and early 2000's. He's still at it and can only be positive for RNN.
7/7/12
• !Report Abuse
Add a reply...

140 characters

RNN Rexahn Pharmaceuticals Inc

RNN

Rexahn Pharmaceuticals Inc